BioCentury
ARTICLE | Company News

Qiagen deal

March 9, 2015 7:00 AM UTC

Qiagen’s Qiagen Marseille subsidiary proposed to spin out its leukemia diagnostic manufacturing capacity and other R&D into a standalone company named HalioDx. HalioDx will be granted a non-exclusive license to Qiagen’s pyrosequencing technology. The subsidiary’s management team will join HalioDx. Qiagen Marseille will continue to generate revenue through contracts with Qiagen. ...